FR18C1029I1 - - Google Patents

Info

Publication number
FR18C1029I1
FR18C1029I1 FR18C1029C FR18C1029I1 FR 18C1029 I1 FR18C1029 I1 FR 18C1029I1 FR 18C1029 C FR18C1029 C FR 18C1029C FR 18C1029 I1 FR18C1029 I1 FR 18C1029I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR18C1029I1 publication Critical patent/FR18C1029I1/fr
Application granted granted Critical
Publication of FR18C1029I2 publication Critical patent/FR18C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR18C1029C 2003-05-02 2018-07-06 Dihydroquinazolines substituees a proprietes antivirales Active FR18C1029I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Publications (2)

Publication Number Publication Date
FR18C1029I1 true FR18C1029I1 (zh) 2018-08-17
FR18C1029I2 FR18C1029I2 (fr) 2020-07-17

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1029C Active FR18C1029I2 (fr) 2003-05-02 2018-07-06 Dihydroquinazolines substituees a proprietes antivirales

Country Status (39)

Country Link
US (4) US7196086B2 (zh)
EP (1) EP1622880B3 (zh)
JP (1) JP4733631B2 (zh)
KR (1) KR100927063B1 (zh)
CN (1) CN100393706C (zh)
AR (1) AR044078A1 (zh)
AT (1) ATE355280T1 (zh)
AU (1) AU2004233978B2 (zh)
BR (1) BRPI0410029B8 (zh)
CA (1) CA2524069C (zh)
CL (1) CL2004000930A1 (zh)
CO (1) CO5700764A2 (zh)
CY (2) CY1106476T1 (zh)
DE (2) DE10319612A1 (zh)
DK (1) DK1622880T6 (zh)
EC (1) ECSP056138A (zh)
EG (1) EG25273A (zh)
ES (1) ES2284007T7 (zh)
FR (1) FR18C1029I2 (zh)
HK (1) HK1092463A1 (zh)
HN (1) HN2004000146A (zh)
HU (2) HUS1800018I1 (zh)
IL (1) IL171513A (zh)
MA (1) MA27794A1 (zh)
MX (1) MXPA05011707A (zh)
MY (1) MY144616A (zh)
NL (1) NL300933I2 (zh)
NO (2) NO333265B3 (zh)
NZ (1) NZ543317A (zh)
PE (1) PE20050145A1 (zh)
PL (1) PL1622880T6 (zh)
PT (1) PT1622880E (zh)
RU (1) RU2360912C2 (zh)
SI (1) SI1622880T1 (zh)
TW (1) TWI335912B (zh)
UA (1) UA82519C2 (zh)
UY (1) UY28294A1 (zh)
WO (1) WO2004096778A1 (zh)
ZA (1) ZA200508710B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
MX2015017758A (es) * 2013-06-19 2016-06-21 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral.
US9890128B2 (en) 2013-12-12 2018-02-13 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2017091453A1 (en) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
EP3498715B1 (en) * 2016-08-08 2021-06-09 Medshine Discovery Inc. Anti-hcmv virus compound
US11174270B2 (en) 2018-02-08 2021-11-16 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
KR20230170813A (ko) 2018-09-12 2023-12-19 노파르티스 아게 항바이러스 피리도피라진디온 화합물
KR20220070005A (ko) 2019-09-26 2022-05-27 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39098A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
UY39097A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
UY39096A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
ATE305933T1 (de) * 2000-07-31 2005-10-15 Hoffmann La Roche Piperazin derivate
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
CN1516695A (zh) 2001-04-19 2004-07-28 用作抗病毒剂的芳基磺酰胺类化合物
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) * 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
KR20080009048A (ko) * 2005-01-25 2008-01-24 프롤렉시스 파마슈티칼스, 인크. 항종양제로서 퀴녹살린 유도체
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ES2336603T3 (es) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
MX2015017758A (es) * 2013-06-19 2016-06-21 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral.

Also Published As

Publication number Publication date
CY2018019I2 (el) 2018-12-12
DE502004003052D1 (de) 2007-04-12
CA2524069A1 (en) 2004-11-11
SI1622880T1 (sl) 2007-08-31
JP4733631B2 (ja) 2011-07-27
IL171513A (en) 2011-11-30
NO2018022I1 (no) 2018-07-04
USRE49698E1 (en) 2023-10-17
HN2004000146A (es) 2008-06-24
HUS1800028I1 (hu) 2018-07-30
ATE355280T1 (de) 2006-03-15
JP2006525249A (ja) 2006-11-09
CO5700764A2 (es) 2006-11-30
AU2004233978A1 (en) 2004-11-11
BRPI0410029B8 (pt) 2021-06-15
MXPA05011707A (es) 2006-02-13
USRE46791E1 (en) 2018-04-17
FR18C1029I2 (fr) 2020-07-17
BRPI0410029A (pt) 2006-04-25
PE20050145A1 (es) 2005-05-22
TW200510343A (en) 2005-03-16
CA2524069C (en) 2011-11-08
CN100393706C (zh) 2008-06-11
DK1622880T3 (da) 2007-06-25
NO333265B1 (no) 2013-04-22
ECSP056138A (es) 2006-04-19
BRPI0410029B1 (pt) 2019-12-31
PL1622880T6 (pl) 2018-08-31
CL2004000930A1 (es) 2005-03-18
PL1622880T3 (pl) 2007-08-31
EP1622880B3 (de) 2018-05-23
TWI335912B (en) 2011-01-11
HUS1800018I1 (hu) 2018-05-28
US20050065160A1 (en) 2005-03-24
RU2360912C2 (ru) 2009-07-10
NL300933I2 (nl) 2018-04-26
US7196086B2 (en) 2007-03-27
ES2284007T7 (es) 2018-06-20
EP1622880B1 (de) 2007-02-28
RU2005137276A (ru) 2006-07-27
ZA200508710B (en) 2006-12-27
UY28294A1 (es) 2004-11-30
UA82519C2 (uk) 2008-04-25
DK1622880T6 (da) 2018-06-18
KR20060009883A (ko) 2006-02-01
US8513255B2 (en) 2013-08-20
KR100927063B1 (ko) 2009-11-13
EP1622880A1 (de) 2006-02-08
ES2284007T3 (es) 2007-11-01
NZ543317A (en) 2008-05-30
NO20055649L (no) 2006-01-31
CY1106476T1 (el) 2012-01-25
CY2018019I1 (el) 2018-12-12
HK1092463A1 (en) 2007-02-09
AR044078A1 (es) 2005-08-24
MY144616A (en) 2011-10-14
NO333265B3 (no) 2019-06-03
US20070191387A1 (en) 2007-08-16
PT1622880E (pt) 2007-06-04
WO2004096778A1 (de) 2004-11-11
EG25273A (en) 2011-12-04
DE10319612A1 (de) 2004-11-18
AU2004233978B2 (en) 2010-02-11
MA27794A1 (fr) 2006-03-01
CN1784390A (zh) 2006-06-07
NO20055649D0 (no) 2005-11-30

Similar Documents

Publication Publication Date Title
FR18C1029I1 (zh)
BE2015C007I2 (zh)
BE2014C055I2 (zh)
BE2014C027I2 (zh)
BE2014C003I2 (zh)
BE2013C075I2 (zh)
BE2013C070I2 (zh)
BE2013C067I2 (zh)
JP2003318781A5 (zh)
JP2003331592A5 (zh)
BE2015C005I2 (zh)
JP2004031937A5 (zh)
JP2004038148A5 (zh)
JP2004007966A5 (zh)
JP2004034026A5 (zh)
JP2004020567A5 (zh)
JP2004221534A5 (zh)
JP2003338368A5 (zh)
JP2004215867A5 (zh)
JP2004215874A5 (zh)
JP2004139014A5 (zh)
JP2004229160A5 (zh)
BE2015C024I2 (zh)
AU2002256398A1 (zh)
AU2002327736A1 (zh)